Scynexis (SCYX) Cash from Financing Activities (2013 - 2026)
Scynexis' (SCYX) quarterly Cash from Financing Activities came in at $24.0 million in Q1 2026, up 270.68% YoY from $6.5 million in Q1 2025, and up 21002.61% on a QoQ basis from -$115000.0 in Q4 2025.
Scynexis (SCYX) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Cash from Financing Activities data on file, last reported at $24.0 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 270.68% year-over-year to $24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (up 268.58% YoY) and the FY2025 annual result came in at -$14.2 million, down 10094.24% from the prior year.
- Cash from Financing Activities advanced to $24.0 million in Q1 2026, from -$115000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $42.1 million in Q2 2022 to a low of -$36.6 million in Q2 2023.
- A 5-year average of $1.5 million and a median of $3500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 9569.01% — and 2025, when it plunged 93793.33%.
- Tracing SCYX's Cash from Financing Activities over 5 years: stood at -$183000.0 in 2022, then grew by 26.23% to -$135000.0 in 2023, then dropped by 14.81% to -$155000.0 in 2024, then increased by 25.81% to -$115000.0 in 2025, then jumped by 21002.61% to $24.0 million in 2026.
- The last three Cash from Financing Activities figures came in at $24.0 million (Q1 2026), -$115000.0 (Q4 2025), and $29000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - | 13.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.46 Mn |
| Jun 30, 2026 | 13.46 Mn |
| Mar 31, 2026 | 24.04 Mn |
| Mar 31, 2026 | 24.04 Mn |
| Dec 31, 2025 | -115,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Sep 30, 2025 | 29,000.00 |
| Mar 31, 2025 | -14.08 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2024 | -155,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Dec 31, 2023 | -135,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Sep 30, 2023 | 34,000.00 |